OpenASO: RNA Rescue—designing splice-modulating antisense oligonucleotides through community science

  1. Michael D. Stone2,5
  1. 1Department of Molecular, Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz, California 95064, USA
  2. 2Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, California 95064, USA
  3. 3Eterna Massive Open Laboratory
  4. 4Howard Hughes Medical Institute, Stanford, California 94305, USA
  5. 5Department of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, California 95064, USA
  6. 6Department of Biochemistry, Stanford University, Stanford, California 94305, USA
  7. 7Department of Physics, Stanford University, Stanford, California 94305, USA
  1. Corresponding authors: mds{at}ucsc.edu, jsanfor2{at}ucsc.edu
  1. Handling editor: Michelle Hastings

Abstract

Splice-modulating antisense oligonucleotides (ASOs) are precision RNA-based drugs that are becoming an established modality to treat human disease. Previously, we reported the discovery of ASOs that target a novel, putative intronic RNA structure to rescue splicing of multiple pathogenic variants of F8 exon 16 that cause hemophilia A. However, the conventional approach to discovering splice-modulating ASOs is both laborious and expensive. Here, we describe a novel approach that integrates data-driven RNA structure prediction and community science to discover splice-modulating ASOs. Using a splicing-deficient pathogenic variant of F8 exon 16 as a model, we show that 25% of the top-scoring molecules designed in the Eterna OpenASO challenge have a statistically significant impact on enhancing exon 16 splicing. Additionally, we show that a distinct combination of ASOs designed by Eterna players can additively enhance the inclusion of the splicing-deficient exon 16 variant. Together, our data suggest that crowdsourcing designs from a community of citizen scientists may accelerate and complement traditional avenues for the discovery of splice-modulating ASOs with potential to treat human disease.

Keywords

Footnotes

  • Received October 15, 2024.
  • Accepted May 6, 2025.

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

| Table of Contents